Sun Chief Sees ‘New Normal’ For First-To-File ANDAs Amid US Price Pressure
Executive Summary
Sun Pharmaceutical Industries reported weak fourth quarter earnings amid US pricing pressure and the management has signaled a challenging FY2018 in store.
You may also be interested in...
Lupin Reviews R&D Thrust, Biosimilars Plan On Course
Lupin is reorienting its R&D priorities with a thrust on more definitive, near and mid-term opportunities while rationalizing its discovery program and trimming its headcount. The firm’s biosimilars program though remains on track with a filing anticipated in Europe and Japan this fiscal.
Indian Generics Firms Must Shift Gears For Third Wave, Says Lupin MD
Indian firms must transition from “plain-vanilla” generics to more complex products, including biosimilars, if they want to continue growing. However, returns from the sector’s so-called Third Wave will be some time coming, warns Lupin’s managing director Nilesh Gupta.
Indian Generics Firms Must Shift Gears For Third Wave, Says Lupin MD
Indian firms must transition from “plain-vanilla” generics to more complex products, including biosimilars, if they want to continue growing. However, returns from the sector’s so-called Third Wave will be some time coming, warns Lupin’s managing director Nilesh Gupta.